These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 31021010)

  • 41. Skin-mucous membrane disorder and therapeutic effect of pegylated liposomal doxorubicin in recurrent ovarian cancer.
    Yamada Y; Kawaguchi R; Ito F; Iwai K; Niiro E; Shigetomi H; Tanase Y; Kobayashi H
    J Obstet Gynaecol Res; 2017 Jul; 43(7):1194-1199. PubMed ID: 28544386
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Selective cardiac surveillance in patients with gynecologic cancer undergoing treatment with pegylated liposomal doxorubicin (PLD).
    Kushnir CL; Angarita AM; Havrilesky LJ; Thompson S; Spahlinger D; Sinno AK; Tanner EJ; Secord AA; Roche KL; Stone RL; Fader AN
    Gynecol Oncol; 2015 Jun; 137(3):503-7. PubMed ID: 25735254
    [TBL] [Abstract][Full Text] [Related]  

  • 43. ["Hand-foot" syndrome--after liposomal pegylated doxorubicin in patients with the ovarian cancer recurrence (own experiences)].
    Mrochen-Domin I; Nowara E; Kaleta B
    Ginekol Pol; 2008 May; 79(5):332-7. PubMed ID: 18624107
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Grade 3 liposomal-doxorubicin-induced skin toxicity in a patient following complete resolution of moderately severe sunburn.
    Markman M; Kulp B; Peterson G
    Gynecol Oncol; 2004 Aug; 94(2):578-80. PubMed ID: 15297208
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intertriginous pattern of toxic erythema of chemotherapy.
    Carvalho R; Macias V; Marques-Pinto G; Afonso A; Cardoso J
    Cutan Ocul Toxicol; 2011 Dec; 30(4):309-11. PubMed ID: 21501039
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety and efficacy of pegylated liposomal doxorubicin-based adjuvant chemotherapy in patients with stage I-III triple-negative breast cancer.
    Lien MY; Liu LC; Wang HC; Yeh MH; Chen CJ; Yeh SP; Bai LY; Liao YM; Lin CY; Hsieh CY; Lin CC; Li LY; Lin PH; Chiu CF
    Anticancer Res; 2014 Dec; 34(12):7319-26. PubMed ID: 25503167
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO.
    Oskay-Oezcelik G; Koensgen D; Hindenburg HJ; Klare P; Schmalfeldt B; Lichtenegger W; Chekerov R; Al-Batran SE; Neumann U; Sehouli J;
    Anticancer Res; 2008; 28(2B):1329-34. PubMed ID: 18505074
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pegylated-liposomal Doxorubicin-induced Glomerular Thrombotic Microangiopathy.
    Yokoyama S; Kakeshita K; Imamura T; Shima T; Fujioka H; Yamazaki H; Koike T; Kinugawa K
    Intern Med; 2024 Oct; 63(20):2839-2845. PubMed ID: 38462521
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer.
    Colombo N; Kutarska E; Dimopoulos M; Bae DS; Rzepka-Gorska I; Bidzinski M; Scambia G; Engelholm SA; Joly F; Weber D; El-Hashimy M; Li J; Souami F; Wing P; Engelholm S; Bamias A; Schwartz P
    J Clin Oncol; 2012 Nov; 30(31):3841-7. PubMed ID: 22987083
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Extracorporeal Elimination of Circulating Pegylated Liposomal Doxorubicin (PLD) to Enhance the Benefit of Cytostatic Therapy in Platinum-Resistant Ovarian Cancer Patients.
    Kubeček O; Bláha M; Diaz-Garcia D; Filip S
    Acta Medica (Hradec Kralove); 2015; 58(1):3-8. PubMed ID: 26454800
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study.
    Sehouli J; Camara O; Schmidt M; Mahner S; Seipelt G; Otremba B; Schmalfeldt B; Tesch H; Lorenz-Schlüter C; Oskay-Ozcelik G;
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):585-91. PubMed ID: 19156414
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Flagellate erythema secondary to bleomycin: a new case report and review of the literature.
    Khmamouche MR; Debbagh A; Mahfoud T; Aassab R; Lkhoyaali S; Ichou M; Errihani H
    J Drugs Dermatol; 2014 Aug; 13(8):983-4. PubMed ID: 25116979
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Plasma filtration for the controlled removal of liposomal therapeutics - From the apheretic site of view.
    Blaha M; Martinkova J; Lanska M; Filip S; Malakova J; Kubecek O; Bezouska J; Spacek J
    Atheroscler Suppl; 2017 Nov; 30():286-293. PubMed ID: 29096853
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immediate hypersensitivity reaction to pegylated liposomal doxorubicin: management and outcome in four patients.
    Ingen-Housz-Oro S; Pham-Ledard A; Brice P; Lebrun-Vignes B; Zehou O; Reitter D; Ram-Wolff C; Dupin N; Bagot M; Chosidow O; Beylot-Barry M
    Eur J Dermatol; 2017 Jun; 27(3):271-274. PubMed ID: 28524061
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Correlation of toxicity and efficacy with pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) (Caelyx®).
    Boers-Sonderen MJ; van Herpen CM; van der Graaf WT; Desar IM; van der Logt MG; de Beer YM; Ottevanger PB; van Erp NP
    Cancer Chemother Pharmacol; 2014 Sep; 74(3):457-63. PubMed ID: 24965180
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Patient-reported outcomes in relapsed ovarian cancer: results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD alone.
    Krasner CN; Poveda A; Herzog TJ; Vermorken JB; Kaye SB; Nieto A; Claret PL; Park YC; Parekh T; Monk BJ
    Gynecol Oncol; 2012 Oct; 127(1):161-7. PubMed ID: 22765965
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-term pegylated liposomal doxorubicin use in recurrent ovarian carcinoma.
    Collins Y; Lele S
    J Natl Med Assoc; 2005 Oct; 97(10):1414-6. PubMed ID: 16353663
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Chinese expert consensus on management of adverse events of pegylated liposomal doxorubicin (2020 edition)].
    Breast Cancer Group, Chinese Association for Clinical Oncologist (CACO)
    Zhonghua Zhong Liu Za Zhi; 2020 Aug; 42(8):617-623. PubMed ID: 32867451
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Interstitial pneumonitis induced by pegylated liposomal doxorubicin in a patient with recurrent ovarian cancer.
    Inaba K; Arimoto T; Hoya M; Kawana K; Nakagawa S; Kozuma S; Taketani Y
    Med Oncol; 2012 Jun; 29(2):1255-7. PubMed ID: 21390517
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pyridoxine as prophylactic therapy for palmar-plantar erythrodysesthesia associated with administration of pegylated liposomal doxorubicin (caelyx): a single-center experience.
    Rossi D; Catalano G
    Oncology; 2007; 73(3-4):277-8. PubMed ID: 18424894
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.